Daiichi Puts New Flu Drug In Phase III Trials For H5N1 Effectiveness
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has begun final-stage trials on a flu drug that could be effective against the bird flu virus. Daiichi's CS-8958 is to undergo its Phase III trial in Japan, Hong Kong, South Korea and Taiwan over the next four months, with influenza A or B patients the participants. The drug is to be tested in comparison with Roche's Tamiflu. Daiichi expects to file an approval application in Japan later next year. Daiichi also has begun separate trials for use of the drug as a pediatric treatment. (Click here for more - a subscription may be required
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.